Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
Launched by NAGOYA UNIVERSITY · Mar 22, 2016
Trial Information
Current as of April 28, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Borderline resectable pancreatic cancer (based on NCCN guideline version 2.2015)
- • 2. first treatment for pancreatic cancer
- • 3. performance status 0 or 1
- • 4. adequate one marrow function
- • 5. adequate renal function
- • 6. obtained informed consent
- Exclusion Criteria:
- • 1. other active concomitant malignancies
- • 2. other severe medical conditions; contraindication of FOLFIRINOX, paclitaxel and gemcitabine
- • 3. pregnant women
- • 4. no informed consent
About Nagoya University
Nagoya University, a prestigious institution located in Japan, is dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Nagoya University leverages its cutting-edge facilities and expertise in various fields of medicine to conduct rigorous studies that aim to address critical health challenges. The university is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the safety and well-being of participants while striving to translate research findings into meaningful clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials